AC Immune is currently undervalued with a gap of 205.8% relative to the price target.
The current price is $2.78, which places AC Immune in the undervalued category. The stock is considered undervalued when the price is below $7.65, and overvalued when the price exceeds $9.35.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For AC Immune, the fair value range lies between $7.65 and $9.35.
4 analysts cover AC Immune. There is broad agreement on a positive view — 100% recommend buying. The average price target is $8.50, which gives an upside of 205.8% from the current price.
AC Immune is classified as a speculative stock.
The P/S ratio is 16.2 (high — the market pays a premium for the revenue). The P/B ratio is 6.7.
AC Immune and an operating margin of 7.9%.
The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is -12.88 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 105.7% — moderate debt.
Short interest is 7.33% — elevated, some investors are betting on a decline.
In 2026, insiders at AC Immune have made 2 transactions, all of which were sales. On a net basis, insiders took 59,300 $ out of the stock. Active insiders include Pfeifer Andrea.
There has been no insider trading in the last 3 months.
Insiders have exclusively sold shares in the recent period. This can suggest management sees limited opportunity.
Across the last 2 transactions: 0 purchases and 2 sales. A net 59,300 $ out of the stock.
Latest sale: Pfeifer Andrea sold 10,000 shares at 3 $ each on 2026-05-15.
Who is selling: Pfeifer Andrea.
The table shows the last 2 reported insider transactions in AC Immune. Green rows are purchases, red rows are sales. The data is based on official filings.
| Transaction date | Name | Type | Number of shares | Price per share ($) | Total amount ($) |
|---|---|---|---|---|---|
| 2026-05-15 | Pfeifer Andrea | Sell | 10,000 | 3 | 27,900 |
| 2026-04-15 | Pfeifer Andrea | Sell | 10,000 | 3 | 31,400 |
The following insiders have sold shares: Pfeifer Andrea. In total, 59,300 $ was sold across 2 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated September 9, 2026.
AC Immune SA is in a short-term uptrend. The price of $2.78 is 2.7% above the 20-day average ($2.71). Medium term, the picture is positive: the price is 11.4% above the 50-day average ($2.50). Long term, the stock is 1.9% below the 200-day average ($2.84), which signals a long-term downtrend.
Death Cross: The 50-day average (2.50) is below the 200-day average (2.84), which is a classic bearish signal for AC Immune SA.
AC Immune SA has an RSI of 56.4. The stock shows positive momentum in the upper part of the neutral zone.
Daily MACD: MACD is positive (0.103), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is above the signal line (0.100) by 0.003, which confirms rising momentum in the uptrend.
Weekly MACD: MACD5 is negative (-0.064), which indicates a broader bearish long-term trend. MACD5 is above the signal line (-0.116) by 0.052, which suggests the negative long-term momentum is fading – a bigger trend reversal could be ahead.
Overall MACD assessment: The daily and weekly MACD give conflicting signals. The short-term trend is bullish, but the long-term trend is still bearish. Weekly momentum is rising, though, which could signal an upcoming trend reversal.
AC Immune SA has an annual standard deviation of 76.3%, which classifies the stock as Extremely speculative. Only risk-tolerant investors should consider this stock, because the price swings can be very large.
Trend: Neutral/mixed.
MACD trend (zero line): Daily bullish (0.103). Weekly bearish (-0.064).
MACD momentum (signal): Daily rising. Weekly rising.
RSI: 56.4 – neutral.
Technical signal: Hold
The signals are mixed – trend and MACD point in different directions. Wait until MACD crosses the zero line in the direction of the trend before acting.
Compare AC Immune with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.
See all 104 stocks in the Healthcare sector